The role of essential fatty acids in chronic fatigue syndrome - A case-controlled study of red-cell membrane essential fatty acids (EFA) and a placebo-controlled treatment study with high dose of EFA
G. Warren et al., The role of essential fatty acids in chronic fatigue syndrome - A case-controlled study of red-cell membrane essential fatty acids (EFA) and a placebo-controlled treatment study with high dose of EFA, ACT NEUR SC, 99(2), 1999, pp. 112-116
Objective - To replicate the treatment study by Behan et al. (1990) using c
urrent research criteria for Chronic Fatigue Syndrome (CFS). Method - Fifty
patients who fulfilled the Oxford Criteria for CFS were randomly allocated
to treatment with either Efamol Marine or placebo for 3 months. They were
seen monthly and completed a physical symptoms checklist and the Beck Inven
tory for Depression and reported if they were the same, better or worse at
the end of the study. Results - Symptoms generally improved with time but.
not significantly and there were no significant differences between the tre
atment and placebo groups. Pretreatment red-cell membrane (RBC) lipids of p
atients compared with age- and sex-matched normal controls showed no signif
icant differences. Discussion - The results of this study contrast sharply
with the previous study where 85% of patients had a clinically significant
improvement of symptoms with Efamol Marine over a 3-month treatment period.